AU2007238676A1 - Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders - Google Patents

Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders Download PDF

Info

Publication number
AU2007238676A1
AU2007238676A1 AU2007238676A AU2007238676A AU2007238676A1 AU 2007238676 A1 AU2007238676 A1 AU 2007238676A1 AU 2007238676 A AU2007238676 A AU 2007238676A AU 2007238676 A AU2007238676 A AU 2007238676A AU 2007238676 A1 AU2007238676 A1 AU 2007238676A1
Authority
AU
Australia
Prior art keywords
alkyl
aryl
hydrogen
optionally substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007238676A
Other languages
English (en)
Inventor
Rishi Kumar Jain
Joseph Kelleher Iii
Stefan Peukert
Yingchuan Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2007238676A1 publication Critical patent/AU2007238676A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2007238676A 2006-04-14 2007-04-12 Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders Abandoned AU2007238676A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79216206P 2006-04-14 2006-04-14
US60/792,162 2006-04-14
PCT/US2007/009138 WO2007120827A2 (en) 2006-04-14 2007-04-12 Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders

Publications (1)

Publication Number Publication Date
AU2007238676A1 true AU2007238676A1 (en) 2007-10-25

Family

ID=38474269

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007238676A Abandoned AU2007238676A1 (en) 2006-04-14 2007-04-12 Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders

Country Status (11)

Country Link
US (1) US20090306149A1 (enExample)
EP (1) EP2010170A2 (enExample)
JP (1) JP2009536156A (enExample)
KR (1) KR20090006089A (enExample)
CN (1) CN101420949A (enExample)
AU (1) AU2007238676A1 (enExample)
BR (1) BRPI0710723A2 (enExample)
CA (1) CA2648196A1 (enExample)
MX (1) MX2008013204A (enExample)
RU (1) RU2008144805A (enExample)
WO (1) WO2007120827A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN104059124A (zh) 2007-12-27 2014-09-24 无限药品股份有限公司 立体选择性还原的方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009217982B2 (en) * 2008-02-26 2013-04-11 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
EP2334683B1 (en) * 2008-08-29 2017-03-22 MSD Italia S.r.l. Saturated bicyclic heterocyclic derivatives as smo antagonists
WO2010037715A1 (en) * 2008-10-01 2010-04-08 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
PE20180318A1 (es) 2011-01-10 2018-02-09 Infinity Pharmaceuticals Inc Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
AU2012249801B2 (en) 2011-04-25 2016-05-19 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
WO2014085523A1 (en) 2012-11-29 2014-06-05 Strasspharma Llc Methods of modulating follicle stimulating hormone activity
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
EP3003309B1 (en) 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6796638B2 (ja) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
GB9807903D0 (en) * 1998-04-14 1998-06-10 Smithkline Beecham Plc Novel compounds
US6197798B1 (en) * 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
CO5090829A1 (es) * 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
WO2000051628A2 (en) * 1999-03-03 2000-09-08 Biogen, Inc. Methods of modulating lipid metabolism and storage
AU6824700A (en) * 1999-07-20 2001-02-05 Novartis Ag Organic compounds
EP1259484B1 (en) * 2000-01-18 2005-05-18 Novartis AG Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion

Also Published As

Publication number Publication date
KR20090006089A (ko) 2009-01-14
CA2648196A1 (en) 2007-10-25
WO2007120827A3 (en) 2007-12-13
MX2008013204A (es) 2008-10-22
BRPI0710723A2 (pt) 2012-01-31
RU2008144805A (ru) 2010-05-20
CN101420949A (zh) 2009-04-29
WO2007120827A2 (en) 2007-10-25
EP2010170A2 (en) 2009-01-07
US20090306149A1 (en) 2009-12-10
JP2009536156A (ja) 2009-10-08

Similar Documents

Publication Publication Date Title
AU2007238676A1 (en) Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
JP5694172B2 (ja) カルバゾール化合物および当該化合物の治療用途
CN101820950B (zh) 作为刺猬蛋白信号通路调节剂的联苯基甲酰胺类化合物
CN117597341A (zh) 磺酰胺衍生物、其制备方法及其在医药上的应用
SG182205A1 (en) Organic compounds and their uses
TW200800894A (en) Carboxyamine compounds and methods of use thereof
CN113993845A (zh) 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物
CN111533721B (zh) 苯并吡喃酮或喹啉酮类化合物及其应用
CN118221685A (zh) 作为kras g12d抑制剂的吲哚类化合物
KR101475168B1 (ko) 암 치료용 신규 ｎ-하이드록시-벤즈아마이드
CN110072526A (zh) 治疗癌症的激酶抑制剂化合物、组合物和方法
WO2001064680A1 (en) Myt1 kinase inhibitors
CA3174266A1 (en) Grk2 inhibitors and uses thereof
CN116535400A (zh) 氮杂螺环化合物及其应用
WO2025131131A1 (zh) Hdac抑制剂、组合物及其用途
WO2020114519A1 (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
CN112010789A (zh) 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
JP7293493B2 (ja) ７，８－ジヒドロ－４Ｈ－ピラゾロ［４，３－ｃ］アゼピン－６－オン化合物
WO2014029250A1 (zh) 苯并吡啶氮杂卓类化合物及其应用
CN113620873B (zh) 含锌结合基以及喹啉骨架的化合物的制备方法和用途
CN101501004A (zh) 作为hedgehog通路调节剂的化合物和组合物
JP2005526026A (ja) カテコール生物学的等価体
JP2025529875A (ja) 新規の置換テトラヒドロイソキノリン－６－カルボン酸誘導体、この誘導体を調製する方法、及びこの誘導体の治療的使用
CN114727975A (zh) 双雄激素受体/akr1c3抑制剂
CN118772141A (zh) 用于治疗癌症的DNA聚合酶Theta抑制剂

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted